Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
about
Antiviral actions of interferonsVirologic Tools for HCV Drug Resistance TestingWide range of quasispecies diversity during primary hepatitis C virus infectionHuman serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infectionGenetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees.Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus QuasispeciesConservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell AttachmentEarly changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcomeCharacterization of hepatitis C virus quasispecies by matrix-assisted laser desorption ionization-time of flight (mass spectrometry) mutation detection.Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.Plasma and Liver Hepatitis C Virus Variability in Patients Coinfected with Human Immunodeficiency VirusSignificance of Pretreatment Analysis of Hepatitis C Virus Genotype 1b Hypervariable Region 1 Sequences To Predict Antiviral OutcomeHepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral TherapyCorrelation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3aThe quasispecies nature and biological implications of the hepatitis C virusQuasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcomeDeep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.Spouse-to-Spouse Transmission and Evolution of Hypervariable Region 1 and 5' Untranslated Region of Hepatitis C Virus Analyzed by Next-Generation SequencingCross-reactivity of hypervariable region 1 chimera of hepatitis C virus.Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions.Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.Inhibition of the interaction between NS3 protease and HCV IRES with a small peptide: a novel therapeutic strategy.
P2860
Q24550676-B687AEE2-D82F-49FE-8C4E-7401D2FBC71BQ26774374-DAEF1888-9D17-4D7E-B00B-FC379BB424AAQ27469430-24FEB203-E5EB-4B1B-A0CA-DE60E3EC550EQ27469507-40404F6B-46D3-4C56-AAC4-4665AE8074B6Q27469620-9F910FEA-5108-46CF-9E9E-06A82ECED83DQ27469647-7FE6E0BD-C06B-4B50-A8D4-B57A3013D8FBQ27469782-71B073C6-DEAE-4A4A-A114-3AC545EFA396Q27469804-103989E8-E774-439E-95EA-830ABD3122FFQ27471683-C00188D2-A87D-42F0-9D6C-75A62F31714CQ27472751-76E9D9BC-1B92-4EF3-9610-652B144C870CQ27472768-787EB474-98C8-407D-8E90-639C2B7D77D7Q27473249-C7941BF9-D8ED-415E-9397-F4E004AA4837Q27478087-725109FE-EB46-4771-ADD8-706E6EE44E49Q27486013-9B3B27F6-7E08-4F83-A182-5096BBD38040Q27486521-3EF11992-3940-4E64-B167-246B8D125A70Q27490497-E1B311C9-0B49-48B0-9FC1-3F8F42FA5FE0Q33834509-61856670-0743-47C7-AA82-72569C981189Q34409020-D7D85F94-B682-4904-BEE6-1B256BEEB6A3Q34485144-01345B66-0DCA-4D8D-8DB7-DC3FCCDF0A40Q35641185-1283039F-A305-4A25-814B-1F98F45160ECQ35936933-D0933494-BE5B-4FD7-875F-E0532C774451Q36179811-8D8BD7E4-A787-4BDC-A4E4-FB6215EB2DB0Q40763228-1F989D85-5003-4CDD-BDCB-8AE8EE92FC75Q41841986-206051A8-0EFC-4D6A-9DCB-458D267F730BQ42540967-75955C56-696F-4E5B-A70B-00C3B3F414E1
P2860
Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@ast
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@en
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@nl
type
label
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@ast
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@en
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@nl
prefLabel
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@ast
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@en
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@nl
P2093
P2860
P921
P1433
P1476
Evolution of the hepatitis C v ...... iving alpha interferon therapy
@en
P2093
D Dhumeaux
G Germanidis
J M Pawlotsky
M Pellerin
P O Frainais
P2860
P304
P577
1999-08-01T00:00:00Z